Yin et al. achieved successful in vivo gene correction of the mutation in Fah, the gene encoding fumarylacetoacetate hydrolase, in a mouse model of hereditary tyrosinemia by HD of CRISPR-Cas9 components along with a donor template DNA. This evidence concerns the gene FAH and tyrosinemia.